NASDAQ:ABVX ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis $9.78 -0.51 (-4.96%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About ABIVAX Société Anonyme Stock (NASDAQ:ABVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ABIVAX Société Anonyme alerts:Sign Up Key Stats Today's Range$9.70▼$10.1850-Day Range$9.78▼$12.7152-Week Range$7.99▼$17.02Volume53,858 shsAverage Volume83,859 shsMarket Capitalization$615.45 millionP/E RatioN/ADividend YieldN/APrice Target$36.50Consensus RatingModerate Buy Company OverviewABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Read More… Next opportunity for crypto millions (Ad)As October unfolds and the effects of the Fed Pivot ripple through the market, this crypto could skyrocket. Want to know more?Click here to discover the altcoin set to dominate October's bull run. ABIVAX Société Anonyme Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreABVX MarketRank™: ABIVAX Société Anonyme scored higher than 47% of companies evaluated by MarketBeat, and ranked 646th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageABIVAX Société Anonyme has only been the subject of 1 research reports in the past 90 days.Read more about ABIVAX Société Anonyme's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.86) per share.Price to Book Value per Share RatioABIVAX Société Anonyme has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.38% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 6.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABIVAX Société Anonyme does not currently pay a dividend.Dividend GrowthABIVAX Société Anonyme does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.38% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 6.87%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.16 News SentimentABIVAX Société Anonyme has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ABVX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ABIVAX Société Anonyme's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVX Stock News HeadlinesABIVAX Société Anonyme (NASDAQ:ABVX) Shares Down 4.9% - Here's What HappenedOctober 4 at 12:01 PM | americanbankingnews.comAbivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's DiseaseOctober 3 at 4:01 PM | globenewswire.comNext opportunity for crypto millionsOctober isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…October 5, 2024 | Crypto 101 Media (Ad)Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label MaintenanceOctober 3 at 2:31 AM | globenewswire.comABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Volume IncreaseOctober 1, 2024 | americanbankingnews.comAbivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024September 26, 2024 | globenewswire.comAbivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse ModelSeptember 25, 2024 | globenewswire.comABIVAX Société Anonyme (NASDAQ:ABVX) Receives $36.50 Consensus Target Price from AnalystsSeptember 25, 2024 | americanbankingnews.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? ABIVAX Société Anonyme's stock was trading at $10.70 on January 1st, 2024. Since then, ABVX stock has decreased by 8.6% and is now trading at $9.78. View the best growth stocks for 2024 here. When did ABIVAX Société Anonyme IPO? ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share. How do I buy shares of ABIVAX Société Anonyme? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today10/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CUSIPN/A CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$36.50 High Stock Price Target$50.00 Low Stock Price Target$16.00 Potential Upside/Downside+273.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.48 Current Ratio3.04 Quick Ratio4.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book2.90Miscellaneous Outstanding Shares62,929,000Free FloatN/AMarket Cap$615.45 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ABVX) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.